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Insulin resistance in skeletal muscle is manifested by decreased insulin-stimulated glucose uptake and results from impaired
insulin signaling and multiple post-receptor intracellular defects including impaired glucose transport, glucose phosphorylation,
and reduced glucose oxidation and glycogen synthesis. Insulin resistance is a core defect in type 2 diabetes, it is also associated
with obesity and the metabolic syndrome. Dysregulation of fatty acid metabolism plays a pivotal role in the pathogenesis of
insulin resistance in skeletal muscle. Recent studies have reported a mitochondrial defect in oxidative phosphorylation in skeletal
muscle in variety of insulin resistant states. In this review, we summarize the cellular and molecular defects that contribute to the
development of insulin resistance in skeletal muscle.
1.Introduction
Skeletal muscle is the major site for disposal of ingested
glucose in lean healthy normal glucose tolerance (NGT)
individuals [1–4]. Following a meal, approximately one
third of ingested glucose is taken up by the liver and
the rest by peripheral tissues, primarily skeletal muscle via
an insulin dependent mechanism [1–4]. The postprandial
hyperglycemiastimulatesinsulinsecretionfromthepancreas
and the rise in plasma insulin concentration stimulates
glucose uptake in skeletal muscle leading to the disposal of
ingested glucose [1–4].
In insulin resistance states, such as T2DM and obesity,
insulin-stimulated glucose disposal in skeletal muscle is
markedly impaired [1–6]. The decreased insulin-stimulated
glucose uptake is due to impaired insulin signaling and mul-
tiple postreceptor intracellular defects including impaired
glucose transport and glucose phosphorylation, and reduced
glucose oxidation and glycogen synthesis [7–10]( Table 1).
Althoughtheexactmechanismthatleadstothedevelopment
of insulin resistance in skeletal muscle is not yet fully
understood,anincreasedintramyocellarfatcontentandfatty
acid metabolites have been shown to play a pivotal role
in the development of insulin resistance in skeletal muscle
[11–15]. The recent studies have reported the existence of a
defectinmitochondrialoxidativephosphorylationinskeletal
muscle in insulin resistance states [16–20]a n ds u g g e s t
that this mitochondrial defect contributes to the increased
intramyocellar fat content. In this paper we will summarize
the evidence that supports the existence of insulin resistance
in skeletal muscle, the cellular mechanism(s) that lead
to the development of insulin resistance, and the clinical
consequences of insulin resistance in skeletal muscle.
2.Normal SkeletalMuscleMetabolism
Skeletal muscle utilizes both glucose and free fatty acid
(FFA) as fuel sources for energy production. During the
postabsorptive state, the plasma insulin concentration is low.
Since the plasma insulin concentration is the principal factor
that restrains lipolysis in adipocytes [21] and stimulates
glucose uptake in skeletal muscle [21], during the fasting
state, muscle glucose uptake is low and the plasma FFA
concentration is elevated. Thus, under fasting conditions,
FFA serves as the principal fuel source for energy production
inskeletalmuscle,whilethebrainexclusivelyutilizesglucose.
Following glucose ingestion, the increase in plasma glu-
cose concentration stimulates insulin secretion from the beta
cell and the resultant hyperinsulinemia suppresses lipolysis,
leading to decline in plasma FFA concentration and subse-
quent decrease in the rate of lipid oxidation. Simultaneously,2 Journal of Biomedicine and Biotechnology
Table 1: Defects in Glucose Metabolism in Insulin Resistant
Conditions.
Insulin signaling
(1) Reduced insulin receptor
tyrosine phosphorylation
(2) Decreased IRS-1 tyrosine
phosphorylation
(3) Decreased PI3-kinase
activation
Glucose transport
(1) Impaired GLUT4
translocation
(2) Impaired GLUT 12
translocation
Glucose metabolism
(1) Decreased glucose
phosphorylation
(2) Decreased glucose oxidation
and glycolytic FLUX
(3) Impaired glycogen synthase
insulin stimulates glucose uptake in skeletal muscle, and the
increased glucose ﬂux into skeletal muscle, together with the
activation of key enzymes in glucose metabolism by insulin,
l e a d sam a r k e di n c r e a s ei nm u s c l eg l u c o s eo x i d a t i o n[ 1].
Thus, under postprandial conditions, for example, mixed
meal,muscleenergymetabolismswitchesfrompredominant
oxidizion of fat during the fasting state, to predominant
oxidizion of glucose [22]. The ability of skeletal muscle to
switch from fat oxidation during the fasting state to glucose
oxidation during the postprandial state has been referred to
as metabolic ﬂexibility [23].
After glucose is transported into the myocyte via the
GLUT4 transporter, it is immediately phosphorylated by
hexokinase, and the phosphorylated glucose either is con-
verted to, and stored as glycogen, or enters the glycolytic
pathway for oxidation. Approximately 90% of glucose enter-
ing the glycolysis is oxidized and the remaining 10% is
released as lactate. At low plasma insulin concentration, for
example, fasting state, glycogen synthase, and glucose oxida-
tion contribute equally to glucose disposal. However, with
increasing plasma insulin concentration, glycogen synthase
is activitaed by insulin and glycogen synthesise predominate
(∼70% of glucose disposal) [24].
3. InsulinResistance inSkeletal Muscle
Theterminsulinresistancereferstoanimpairmentininsulin
action in insulin-target tissues, such as skeletal muscle,
adipocytes, and liver. With respect to skeletal muscle, the
primary action of insulin is to stimulate glucose uptake and
metabolism [1–4]. In lean healthy individuals insulin stimu-
lates glucose uptake into skeletal muscle in a dose-dependent
manner, with a half-maximal eﬀect (EC50) at a plasma
insulin concentration ∼60μU/mL [21]. In insulin resistant
states,insulin-stimulatedglucoseuptakeismarkedlyreduced
in skeletal muscle (Figure 1).
Himsworth and kerr [25], using a combined oral glucose
and intravenous tolerance test, were the ﬁrst to demonstrate
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Figure 1: Dose-response curve relating the plasma insulin concen-
tration to the rate of insulin mediated wgole body glucose uptake in
controls and type 2 diabetic subjects. ∗P<. 01 (from [21]).
that tissue sensitivity to insulin is diminished in T2DM
patients. In 1975, Ginsberg et al. [26], using the insulin
suppression test, provided further evidence that the ability
of insulin to promote tissue glucose uptake in T2DM was
severely reduced. The most conclusive documentation for
increased insulin resistance in skeletal muscle in lean, as well
asobeseT2DMsubjects,hasbeenprovidedbyDeFronzoand
colleagues [1–5, 21, 27, 28] and Butterﬁeld and Whichelow
[29]. Using the gold standard euglycemic hyperinsulinemic
clamp technique to quantify insulin-stimulated glucose
uptake, they demonstrated that both lean and obese T2DM
subjectshavemarkeddecrease(>50%)inwholebodyglucose
disposal during the insulin clamp.
Although glucose disposal during the insulin clamp rep-
resents insulin-stimulated glucose uptake by all peripheral
tissues, the great majority of this glucose uptake take place
in skeletal muscle. Under euglycemic conditions studies,
using the insulin clamp in combination with femoral artery
and vein catheterization [5] has shown that approximately
80% of total body glucose uptake occurs in skeletal muscle.
In response to a physiologic increase in plasma insulin
concentration (80–100μU/mL), leg muscle glucose uptake
increases progressively in healthy subjects and reaches a
platue value of approximately 10mg/kglegwt·min. In con-
trast, during the last hour of the insulin clamp study, the
rate of glucose uptake is reduced by ∼50% in lean T2DM
subjects (Figure 2). Thus, the dose response curve relating
insulin-stimulated glucose uptake and the plasma insulin
concentration shifts to the right with an increase in EC50
(to ∼120–140μU/mL) in subjects with T2DM (Figure 1). In
addition, the onset of insulin action in skeletal muscle in
T2DM subjects is markedly delayed (Figure 2). Even though
theinsulininfusioniscontinuedforanadditional60minutes
in subjects with T2DM to allow insulin to more fully express
its biologic action, glucose uptake remains blunted. These
studies indicate that insulin resistance in skeletal muscle in
subjectswithT2DMismaneﬁsted,notonlybyareductionin
the magnitude of insulin action, but also by s delayed onset
of insulin action to stimulate glucose uptake.Journal of Biomedicine and Biotechnology 3
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Figure 2: Insulin-stimulated whole body glucose uptake measured
with the euglycemic clamp in lean healthy and type 2 diabetic
subjects (left) and time course of change in leg glucose uptake in
type 2 diabetic and control subjects (right) (from [5]).
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Figure 3: Insulin-stimulated glucose disposal (40mU/m2·min
euglycemic insulin clamp) in lean healthy control (CON) sub-
jects, lean drug na¨ ıve type 2 diabetic subjects (T2DM), lean
normal-glucose-tolerant (NGT) hypertensive subjects (HTN),
NGT hypertriglyceridemic subjects, and nondiabetic subjects
with coronary artery disease (CAD). The open portion of the
bar represents nonoxidative glucose disposal (glycogen synthe-
sis) and the solid portion represents glucose oxidation. See
DeFronzo and Ferrannini [80], DeFronzo [81].
Insulin resistance in skeletal muscle is manifested long
before the hyperglycemia becomes evident [2]. Thus, lean
healthy oﬀspring of diabetic parents have a signiﬁcant
decrease in insulin-stimulated total body and muscle glucose
disposal which is of a similar magnitude to that observed
in their diabetic parents [30–32]. Insulin resistance in
skeletal muscle also can develop independent of family
history of T2DM. Thus, obese NGT subjects without a
family history for T2DM [33, 34] and individuals with
essential hypertension [35] and ischemic heart disease
[36] also have a 35–50% decrease in whole body insulin-
mediated glucose disposal (Figure 3). Insulin resistance in
skeletal muscle also has been reported in association with
the normal ageing process [37], dyslipidemia (increased
plasma triglyceride/decreased HDL cholesterol) [4, 26],
and in association with many disease states including
polycystic ovary syndrome (PCOs) [38], chronic kidney
failure [39], heart failure [40], myotonic dystrophy [41],
and lipodystrophy [42]. In addition, insulin resistance
develops in acute severe illnesses such as injury and sepsis,
perhaps secondary to the acute inﬂammatory state that
prevails [43]. Insulin resistance in skeletal muscle also can
develop secondary to pharmacological therapy, for example,
glucocorticoids [44], anti-HIV therapy [45], and beta
blockers [46]. These studies indicate that although insulin
resistance in skeletal muscle is a hallmark of T2DM, muscle
insulin resistance and the accompanying insulin resistance
syndrome are more widely prevalent and the metabolic and
clinical consequences of insulin resistance (e.g., increased
cardiovascular risk) aﬀect nondiabetic individuals as
well. Because the molecular mechanisms that lead to the
development of insulin resistance in skeletal muscle have
beenextensivelystudiedinobeseandT2DMsubjects,wewill
focus the discussion on the molecular/biochemical pathways
that cause muscle insulin resistance in these two common
metabolic disorders. However, similar molecular defects
have been reported in other insulin resistant states [39].
Under basal conditions, for example, fasting state, the
plasma insulin concentration is low (5–10μU/mL). Thus,
glucose uptake that takes place in skeletal muscle during the
postabsorptive state is insulin independent. The noninsulin
dependent glucose uptake in skeletal muscle also is decreased
in insulin resistant individuals [47]. The mechanism(s)
responsible for the decrease in noninsulin dependent glucose
uptake has (have) yet to be deﬁned.
3.1. Relationship between Obesity and Insulin Resistance
in Skeletal Muscle. Obese NGT subjects display marked
skeletal muscle insulin resistance compared to lean age
and sex matched individuals [33, 34], and the severity
of muscle insulin resistance is related to the increase in
BMI [34]. Studies in experimental animals and in man
have demonstrated that the increase in body weight is
accompanied with an increase in skeletal muscle insulin
resistance [48–52]. Conversely, weight loss in obese NGT
individuals improves/reverses insulin resistance in skeletal
muscle [43]. Collectively, these studies demonstrate a causal
role of obesity per se in the development of skeletal muscle
insulin resistance.
The mechanism via which obesity causes insulin resis-
tance in skeletal muscle is related to the accumulation of fat
in the myocytes. Muscle biopsy studies [53, 54]h a v ed e m o n -
strated increased triglyceride content in skeletal muscle of
obese NGT subjects compared to lean individuals and an
inverse relationship between muscle insulin sensitivity and
the intramuscular triglyceride content. Although these initial
studies documented the importance of increased muscle
fat content in the etiology of insulin resistance in obesity,
they did not distinguish between the contribution of fat
accumulationinsidethemuscleﬁber(intramyocellar,IMCL)
versus fat accumulation in the muscle outside the muscle cell
(extramyocellar, EMCL). More recent studies [55, 56] using
magnetic resonance spectroscopy have demonstrated that
although IMCL fat content contributes only a small fraction
(∼1%) to the total muscle fat content, it plays a key role4 Journal of Biomedicine and Biotechnology
in the development of insulin resistance in skeletal muscle
compared to EMCL. Muscle insulin resistance strongly
correlateswithIMCL,independentoftotalbodyfatmassand
diabetes status [56], while the correlation between EMCL
and insulin ressitance is not signiﬁcant.
Obese NGT individuals are characterized by an increase
in plasma free fatty acid (FFA) concentration. The important
role of elevated plasma FFA in the pathogenesis of insulin
resistance is now well established [12, 14, 57]. Considerable
data implicate a causative role for elevated plasma FFA level
in insulin resistance in skeletal muscle. The majority of
insulin resistant individuals, both diabetic and nondiabetics,
are overweight or obese [58], and both lean and obese
insulin resistant individuals manifest multiple disturbances
in FFA metabolism [59]. Nondiabetic obese and type 2
diabetic individuals are characterized by day-long elevation
in the plasma FFA concentration, which fails to suppress
normally after ingestion of a mixed meal or an oral glucose
load [60]. Elevated plasma FFA levels correlate strongly
with reduced insulin-stimulated glucose disposal in skeletal
muscle [61]. FFAs are stored within adipocytes in the form
of triglycerides and serve as an important source of energy
during fasting. Insulin is a potent inhibitor of lipolysis and
restrains the release of FFAs from adipocytes. In insulin
resistant individuals, for example, nondiabetic obese and
lean type 2 diabetic subjects, the ability of insulin to inhibit
lipolysis and reduce plasma FFA concentration is markedly
impaired [21, 59], leading to an increased rate of lipolysis
and chronic elevation in the plasma FFA concentration. It is
well established that chronically elevated plasma FFA levels
cause insulin resistance in skeletal muscle [1, 12, 14, 62–
65]. Both acute (4 hours) and chronic (4 days) physiologic
elevation of plasma FFA concentration in insulin sensitive
individualsimpairsinsulinsignalingandcausesinsulinresis-
tanceinskeletalmuscle[28,62–68].Theinhibitionofinsulin
signaling and induction of skeletal muscle insulin resistance
caused by elevation in the plasma FFA concentration is
dose dependent [65]. Conversely, reduction of plasma FFA
concentration in insulin resistant individuals, for example,
type2diabeticsubjects,augmentsinsulin-stimulatedglucose
disposal in skeletal muscle [69–72], and the improvement
in insulin sensitivity is closely associated with a reduction
in intramyocellular FACoA concentration [69]. Collectively,
these results support a causative role of elevated plasma FFA
levels in the pathogenesis of insulin resistance in skeletal
muscle and have been referred to as “lipotoxicity” [73].
Much evidence supports the hypothesis that the lipotoxic
action of FFA on skeletal muscle insulin sensitivity is due
to an increase in intramyocellar fat content: (i) in insulin
resistant individuals, insulin-stimulated glucose disposal
correlatesmorestronglywithintramyocellarfatcontentthan
with the extramtocellar fat [55, 56]; (ii) the decrease in
insulin resistance brought about by reducing the plasma FFA
concentration with acipimox in insulin resistant individuals
isassociatedwithareductioninintracellularFACoAcontent,
and the magnitude of decrease in insulin resistance strongly
correlates with the decrease in FACoA content [69]; (iii)
the increase in insulin resistance caused by elevating the
plasma FFA concentration in insulin sensitive individuals
is associated with an increase in the intramyocellar fat
content [74]; (iv) in animals, a high fat diet causes an
increase in intramuscular fat content, which correlates
closely both with the severity and temporal development
of insulin resistance [75, 76]; (v) in rodents, injection of
recombinant adiponectin increases fat oxidation, reduces
intamyocellular lipid, and improves insulin sensitivity [77];
(vi) muscle-speciﬁc over expression of lipoprotein lipase
leads to the accumulation of fat/FACoA in muscle and
severe muscle insulin resistance, while the fat content and
insulin sensitivity in other tissues, that is, liver, remain
unchanged [78]; (vii) weight loss, induced by bariatric
surgery, results in a complete normalization of insulin
sensitivity despite the presence of continued obesity (BMI
reduced from 49 to 39kg/m2)[ 79]. The normalization of
muscle insulin sensitivity is associated with a reduction of
muscle fat content to normal despite a persistent increase in
total body fat content [79]. These observations collectively
indicate that muscle triglyceride (which is metabolic inert)
is not directly involved in determining insulin sensitivity
but rather represents a marker of imbalance between lipid
supply and lipid oxidation in skeletal muscle, while increases
in intramyocellar FACoA and other lipotoxic metabolites
(DAG, ceramide) have a more direct role in the development
of skeletal muscle insulin resistance.
3.2. Increased Fat Supply or Impaired Mitochondrial Function
in Insulin Resistance? Fat is an important fuel source in
skeletal muscle. The accumulation of fat inside the muscle
ﬁber could originate from excess supply of FFA to the
muscle, a decreased rate of muscle fat oxidation, or some
combination of the two.
3.2.1. Long-Chain Fatty Acid (LCFA) Transport into the
Muscle. Considerabledebateexistsregardingthemechanism
by which LCFAs are transported into skeletal muscle [82–
84]. Because LCFAs are highly hydrophobic molecules and
easily can cross the plasma membrane of muscle via passive
diﬀusion, the rate of LCFA inﬂux into muscle ﬁber is, in
part, driven by the concentration gradient of LCFA across
the plasma membrane. Thus, an increae in plasma FFA
concentration is an important regulator of FFA supply to
skeletal muscle [82]. Indeed, early studies demonstrated
the rate of lipolysis was a key determinant of FFA uptake
and oxidation in skeletal muscle and documented a linear
relationship between the plasma LCFA concentration and
their rate of uptake and oxidation in the muscle [85–87].
More recent studies have reported that under conditions of
marked increase in energy demand in the muscle, for exam-
ple, during exercise, LCFAs uptake initially increases linearly
then plateaus [88], suggesting the existence of a facilitated
transport mechanism for LCFA into skeletal muscle. Three
putative fatty acid binding proteins located at the plasma
membrane have been identiﬁed: (i) the plasma membrane-
bound fatty acid binding protein (FABP); (ii) fatty acid
translocase (CD36); (iii) fatty acid transport protein (FATP).
There is abundant evidence which indicates that CD36 plays
an important role in LCFA uptake into skeletal muscle in
rodents and human and its concentration and activity areJournal of Biomedicine and Biotechnology 5
increased following exercise [89–96]. However, the transport
of LCFA by CD36 into skeletal muscle does not seem to
regulate the rate of LCFA oxidation. During conditions of
decreased fat oxidation and increased CD36 levels, muscle
uptake of LCFA increased, resulting in increased muscle
triglyceride synthesis and increased IMCL content [97, 98].
The CD36 content and LCFA transport capacity have been
reported to be increased in obese and T2DM individuals and
correlatewithincreasedmuscletriglyceridecontent,whilefat
oxidation is decreased. Further, insulin has been reported to
increase CD36 content in skeletal muscle [99].
3.2.2. Fat Oxidation in Insulin Resistance. Several studies
have reported decreased fat oxidation in skeletal muscle,
independent of the plasma FFA concentration [100–102].
In one study that compared muscle fat oxidation across the
leg in obese (BMI = 34kg/m2)c o m p a r e dt ol e a n( B M I=
23kg/m2) individuals, the rate of fatty acid oxidation was
reduced in the obese group despite similar arterial FFA
concentrations [100]. These results suggest the presence of
impaired muscle fat oxidation independent of fat supply
to skeletal muscle. Similar results have been reported in
rectus abdominus muscle in morbidly obese individuals
[101] and in obese nondiabetic women [102]. Studies in
experimental animals also have reported a decreased rate of
lipid oxidation in skeletal muscle in obese Zuker rat [103].
Collectively, these studies indicate the existence of an intren-
sic defect in mitochondrial capacity to oxidize fat in obesity
and T2DM.
3.2.3. Mitochondrial Function in Insulin Resistant Conditions.
Since the majority of fat oxidation take place in the
mitochondria, impaired fat oxidation in insulin resistant
individuals suggests the presence of a mitochondrial defect
that contributes to the impaired muscle fat oxidation and
increased IMCL fat content. Studies in humans, using
molecular, biochemical, and MR spectroscopic techniques,
have documented a defect in mitochondrial oxidative phos-
phorylation in a variety of insulin resistance states. Because
of its accessibility, most of these studies have been per-
formed in skeletal muscle. In vivo measurement of oxidative
phosphorylation with 31P-NMR has demonstrated impaired
ATP synthesis in a variety of insulin resistant states. Lean
normal-glucose-tolerant (NGT), insulin-resistant oﬀspring
of T2DM parents have a 30–40% decrease in metabolic
ﬂux through the tricarboxylic acid cycle [104] and oxida-
tive phosphorylation [31] in skeletal muscle under basal
conditions. A similar impairment in resting ﬂux through
oxidative phosphorylation also has been reported in sub-
jects with type 2 diabetes [105]. Furthermore, unlike lean
insulin-sensitive individuals, both diabetic subjects and
NGT insulin-resistant oﬀspring of two diabetic parents fail
to increase mitochondrial oxidative phosphorylation ﬂux
following insulin stimulation despite a signiﬁcant increase
in glucose disposal in skeletal muscle [105, 106]. Sub-
jects with T2DM also have decreased exercise tolerance
and impaired recovery of intracellular phosphocreatinine
concentration following exercise [107, 108], indicating that
the mitochondrial defect in oxidative phosphorylation may
contribute to the impairment in exercise capacity in insulin-
resistant individuals. Insulin resistance also is a characteristic
feature of the normal aging process and is associated with a
decrease in mitochondrial ATP synthesis rate and an increase
in intramyocellar fat content [109]. Lastly, experimental
induction of insulin resistance in skeletal muscle, by a
physiological increase in plasma FFA concentration in lean
healthy insulin-sensitive individuals, is associated with a
decrease in oxidative phosphorylation ﬂux in skeletal muscle
[110]. Collectively, these results indicate that, regardless of
its etiology, insulin resistance in skeletal muscle is associated
with decreased mitochondrial oxidative phosphorylation.
3.3. Qualitative or Quantitative Mitochondrial Defect. The
mitochondrial defect in ATP synthesis rate documented
in vivo with MRS could be due to a reduction in the
number of mitochondria in skeletal muscle with normal
function of individual mitochondria, an intrinsic defect in
a quantitively normal number of mitochondria, or some
combination of the two. All three of these scenarios would
result in a reduced in ATP synthesis rate measured in
vivo with MRS. Other important unanswered questions are
whether the mitochondrial defect is inherited or acquired
andwhetherthisdefectisthecauseortheeﬀectoftheinsulin
resistance. An acquired defect potentially could be reversed
or prevented, while an inherited defect would be permanent.
Although several lines of evidence support a reduction in
mitochondrial number in skeletal muscle in insulin resistant
individuals, not all studies have yielded consistent results.
Electron microscopic studies have revealed a signiﬁcant
reduction (∼40%) in mitochondrial density in skeletal
muscle in lean NGT oﬀspring of type 2 diabetic parents,
in obese nondiabetic individuals and in T2DM subjects
compared to lean insulin-sensitive, age-matched controls
[111, 112]. The decrease in mitochondrial density in skeletal
muscle in insulin-resistant individuals is consistent with
decreased expression of PGC-1 gene [113], the master
regulator for mitochondrial biogenesis. Diabetic subjects
have been reported to have a decrease in muscle ﬁber oxygen
consumption measured ex vivo. However, when oxygen
consumption was related to mitochondrial copy number,
both diabetic and nondiabetic subjects had similar rates
of muscle oxygen consumption, implying a decrease in
mitochondrial density without an intrinsic mitochondrial
defect in T2DM subjects. However, other studies have
reported contradictory results. Thus, studies which have
assessed mitochondrial copy number in skeletal muscle
in insulin-resistant individuals have reported conﬂicting
results [114–116]. Furthermore, insulin resistance, caused
by physiological elevation in plasma FFA concentration in
leanhealthyindividuals, wasnot associated withasigniﬁcant
change in mitochondrial density in skeletal muscle [117].
Several morphological and functional studies support
the concept of an intrinsic mitochondrial defect in insulin
resistantindividuals.EMstudieshavedemonstratedavariety
of morphological abnormalities in mitochondria in insulin-
resistant individuals [118] and these changes were reversable
with weight loss and increased physical activity [119]. Ex
vivo measurement of electron transport chain activity (ETC)6 Journal of Biomedicine and Biotechnology
[112] and mitochondrial ATP synthesis in isolated mito-
chondria [120, 121] have demonstrated a decrease in ETC
activity and ATP synthesis in obese insulin-resistant indi-
viduals compared to lean insulin-sensitive subjects. Since, in
thesestudies[112,120],ETCactivityandmitochondrialATP
synthesis rate were related to the amount of mitochondrial
protein and/or citrate synthase activity, these observations
indicate the existence of a basic functional defect in mito-
chondrialactivityinskeletalmuscleofobeseinsulin-resistant
individuals [115]. Biochemical studies have reported a
decreaseintheactivityofavarietyofmitochondrialenzymes
[122], also supporting an intrinsic functional mitochondrial
defect in type 2 diabetic subjects. An intrinsic mitochondrial
defect, with or without a decrease in mitochondrial density,
would be expected to result in impaired lipid oxidation, an
increase in intramyocellular lipid content, and the develop-
ment/exacerbation of insulin resistance. Additional studies
are needed to resolve some of the inconsistencies reviewed
above and to explore the biochemical/molecular basis of the
mitochondrial defect measured in vivo in skeletal muscle in
insulin resistant individuals.
3.4. Inherited or Acquired Mitochondrial Defect. An inherited
mitochondrial oxidative defect in the absence (but especially
in the presence) of enhanced FFA inﬂux to skeletal muscle
w o u l db ee x p e c t e dt ol e a dt oi n t r a m y o c e l l u l a rf a ta c c u -
mulation. An inherited defect in mitochondrial oxidative
capacity should be present at or shortly after birth and,
most importantly, not be reversable. With regard to this,
several lines of evidence indicate that the mitochondrial
defect associated with insulin resistant is reversible, at least
in part: (i) modest weight reduction (∼10% of body weight),
produced by dieting and increased physical activity, reduces
insulin resistance and intramyocellular lipid content and
these changes are associated with increased fat oxidation
in skeletal muscle [123]. Furthermore, the magnitude of
increase in fat oxidation following weight loss correlated
strongly with the decrease in insulin resistance [123]; (ii)
marked weight reduction following bariatric surgery in mor-
bidly obese, severely insulin-resistant subjects completely
normalized insulin sensitivity, and correction of the insulin
resistance was accompanied by depletion of intramyocellar
fat content [124]. Although mitochondrial function was
not assessed following weight loss in this latter study,
the depletion of intramyocellular fat and normalization of
insulin sensitivity suggests a reversible mitochondrial defect
in these morbidly obese, insulin-resistant individuals; (iii)
the morphological changes which characterize mitochondria
in obese insulin-resistant individuals [118]c a nb er e v e r s e d
following weight loss and increased physical activity [119];
(iv) the improvement in insulin sensitivity following exercise
is associated with improved muscle oxidative capacity [125,
126] and increases in both mitochondrial density [127]
and activity [128–130]. These observations indicate that the
mitochondrial defect which accompanies insulin resistance
is, at least in part, reversible. The ability to reverse the
defect in mitochondrial oxidative function argues against
an inherited defect. Importantly, a mitochondrial defect
similar to that observed in insulin-resistant individuals can
be produced in young lean healthy subjects by physiologic
elevation of the plasma FFA concentration [110, 131]. In
addition, the insulin resistance associated with aging in lean
subjects with negative family history of diabetes is associated
with a decrease in mitochondrial function [109]. Thus,
normal mitochondrial function in young, insulin-sensitive
subjects suggests that the mitochondrial defect and insulin-
resistance are acquired as part of the normal ageing process.
The evidence reviewed above supports the hypothesis
that the mitochondrial defect which accompanies insulin
resistance is reversible, at least in part, and is likely to be
acquired. Regarding the etiology of the acquired defect in
mitochondrialfunction,invivomitochondrialATPsynthesis
rate, measured with 31P-NMR strongly and inversely corre-
lates with the fasting plasma FFA concentration [105], sug-
gestingapossibleroleforelevatedplasmaFFA/toxicintramy-
ocellar FFA metabolite concentrations in the mitochondrial
dysfunction in insulin resistant individuals. With respect
to this, we recently have demonstrated that a physiologic
increaseinFACoAconcentrationinhibitsmitochondrialATP
synthesis in vitro in mitochondria isolated from skeletal
muscle of NGT healthy lean subjects [132]. This observation
is consistent with the decrease in oxidative phosphorylation
observed following elevation in the plasma FFA concentra-
tion in lean healthy individuals [110], and it indicates that
elevated plasma FFA/intramyocellular metabolite concentra-
tion can cause an acquired mitochondrial defect in oxidative
phosphorylation.
3.5. Mitochondrial Defect in Insulin Resistance: Cause or
Eﬀect? The mitochondrial defect in oxidative phosphory-
l a t i o nd e s c r i b e di nv i v ow i t hM R Sa n de xv i v oi nm u s c l e
ﬁbers and isolated mitochondria could contribute to the
increase in intramyocellar FFA metabolite levels observed in
obesity and T2DM and contribute to the insulin resistance.
However, one also can imagine another scenario in which
the mitochondrial defect results from insulin resistance. If
the increase in intramyocellar fat content in insulin resistant
individuals was associated with an increase in fat oxidation
and excessive production of reactive oxygen species or other
toxic metabolites, then the decrease in mitochondrial oxida-
tive phosphprylation could result from the downregulation
of mitochondrial function to ameliorate the production of
these toxic molecules. Reproduction of the mitochondrial
defect in oxidative phosphorylation in normal healthy
individuals by elevation of the plasma FFA concentration
would argue for a causative role of the mitochondrial defect
ininsulinresistance.However,sincemuscleinsulinresistance
also develops following lipid infusion and since the time
course of the development of the mitochondrial defect and
insulin resistance were not monitored during lipid infusion
[110], one cannot completely exclude the possibility that the
mitochondrial defect results secondary to insulin resistance.
Studies in experimental animals and cultured muscle
cells have attempted to address the relationship between
mitochondrial function and skeletal muscle insulin resis-
tance. Over expression of the PGC-1 alpha gene in skeletal
muscle in mice in vivo enhanced mitochondrial activity,
augmented the expression of multiple proteins involved inJournal of Biomedicine and Biotechnology 7
fat oxidation and glucose transport, and increased by ∼35%
insulin-stimulatedglucoseuptake[133].Similarly,activation
of SIRT1 with resveratrol in mice resulted in increased
mitochondrial activity and protected the animals from diet-
induced obesity and insulin resistance [134]. Studies in
cultured skeletal muscle cells have been inconsistent. Down
regulation of mitochondrial function in myotubes with
oligomycin, which inhibits mitochondrial ATP synthesis,
and with ethidium bromide, which impairs mitochondrial
DNA replication, caused an increase in intracellular fat
content, impaired insulin signaling, and decreased insulin-
stimulated glucose uptake [135]. However, treatment of
the muscle cells with azide, an inhibitor of mitochondrial
complex IV, increased basal glucose uptake without aﬀecting
insulin-stimulated glucose uptake in myotubes [136]. Down
regulation of electron transport chain activity in mice by
knocking down apoptosis inintiating factor (AIF) resulted in
enhanced insulin sensitivity and protection the animal from
fat-induced insulin resistance [137].
In summary it can be concluded that both decreased
mitochondrial fat oxidation and increased FFA inﬂux into
skeletal muscle take place during insulin resistance state.
If the rate of fat supply exceeds the demand for fat
oxidation, the muscle redirects the fat entering the cell
toward triglyceride synthesis leading to increased IMCL
content. In contrast if fat oxidation exceeds the rate of fat
supply, all fat entering the muscle will be directed to fat
oxidation andnofatwillaccumulateinthemuscle.Thus,the
IMCLcontentinskeletalmusclereﬂectsthedynamicbalance
between the demand for fat oxidation and fat supply to
the muscle.
4.CellularMechanismofInsulinResistance
The cellular events via which insulin initiates its stimulatory
eﬀect on glucose metabolism start with binding of the
hormone to speciﬁc receptors that are present on the
muscle cell surface [2, 138–140]. The binding of insulin
activates the insulin receptor and the activated insulin
receptor generates second messengers that activate a cas-
cade of phosphorylation-dephosphorylation reactions that
eventually result in the stimulation of intracellular glucose
metabolism. The ﬁrst step in glucose metabolism involves
activation of the glucose transport system (GLUT4), leading
to glucose inﬂux into muscle cells. The free glucose, which
has entered the cell, subsequently is metabolized by a series
of enzymatic steps that are under the control of insulin. Of
these, the most important are glucose phosphorylation (cat-
alyzed by hexokinase II), glycogen synthase (which controls
glycogen synthesis), and phosphofructokinase (PFK) and
pyruvate dehydrogenase (PDH) (which regulate glycolysis
and glucose oxidation, resp.).
4.1. Insulin Receptor/Insulin Receptor Tyrosine Kinase. The
insulin receptor is a glycoprotein comprised of two α-
subunits and two β-subunits linked by disulﬁde bonds
[2, 138–140]. The two α-subunits of the insulin receptor
are located at the extracellular surface of the muscle plasma
membrane and contain the insulin-binding domain. The
β-subunits have an extracellular domain, a transmembrane
domain, and an intracellular domain that expresses insulin-
stimulated kinase activity directed toward its own tyrosine
residues. The binding of insulin to the α-subunit causes
phosphorylation of the β-subunit on multiple tyrosine
residues. The activation of insulin receptor tyrosine
kinase activity is essential for the action of insulin on
glucose metabolism. Mutagenesis of any of the three major
phosphorylation sites (at residues 1158, 1163, and 1162)
impairs insulin receptor tyrosine kinase activity, leading to
a decrease in the metabolic and growth-promoting eﬀects of
insulin [141, 142].
4.2. Insulin Receptor Signal Transduction. Following the acti-
vation of insulin receptor tyrosine kinase, speciﬁc intracellu-
lar proteins, of which at least nine have been identiﬁed [138,
143], become phosphorylated. In skeletal muscle insulin-
receptor substrate (IRS)-1 serves as the major docking pro-
teinandundergoestyrosinephosphorylationbytheactivated
insulin receptor in regions containing speciﬁc amino acid
sequence motifs (Figure 4). The phosphorylated motifs serve
as recognition sites for proteins containing src-homology 2
(SH2) domains. Mutation of these speciﬁc tyrosine residues
in IRS-1 severely impairs the ability of insulin to stimulate
muscle glycogen synthesis, glucose uptake and oxidation,
and other acute metabolic- and growth-promoting eﬀects of
insulin [142].
The phosphorylated tyrosine residues of IRS-1 mediate
an association with the 85-kDa regulatory subunit of phos-
phatidylinositol 3-kinase (PI3K), leading to activation of the
enzyme [138–140, 143, 144]. PI3K is composed of an 85-
kDa regulatory subunit and a 110-kDa catalytic subunit. The
latter catalyzes the 3  phosphorylation of PI 4-phosphate and
PI 4,5-diphosphate. Activation of PI3K by phosphorylated
IRS-1 leads to activation of protein kinase B/Akt which
is a central intermediate for many of the metabolic and
growth actions of insulin. It has been identiﬁed as one of the
kinases responsible for the inactivation of glycogen synthase
kinase through its phosphorylation, a process that leads to
the activation of glycogen synthase. Akt also phosphorylates
the newly identiﬁed Akt substrate AS160, leading to its
redistribution in the cell and activation of Rab proteins
required for the translocation of the vesicles containing
GLUT4 to the plasma membrane.
Inhibitors of PI3K impair glucose transport and block
the activation of glycogen synthase and hexokinase- (HK-)
II expression [138–146] The action of insulin to increase
protein synthesis and inhibit protein degradation also is
mediated by PI3K.
Other proteins with SH2 domains, including the adapter
protein Grb2 and Shc, also interact with IRS-1 and become
phosphorylated following exposure to insulin [138–140,
143]. Grb2 and Shc link IRS-1/IRS-2 to the mitogen-
activated protein kinase- (MAPK-) signaling pathway, which
plays an important role in the generation of transcription
factors and promotes cell growth, proliferation, and diﬀer-
entiation [138, 143]. Inhibition of the MAPK kinase pathway
prevents the stimulation of cell growth by insulin but has no
eﬀect on the metabolic actions of the hormone [147].8 Journal of Biomedicine and Biotechnology
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Figure 4: Insulin signal transduction system in normal glucose
tolerant subjects (see text for a detailed discussion).
Under anabolic conditions, insulin augments glycogen
synthesis by simultaneously activating glycogen synthase and
inhibiting glycogen phosphorylase [148, 149]. The eﬀect
of insulin is mediated through the PI3K pathway, which
inactivates kinases such as glycogen synthase kinase-3 and
activates phosphatases, particularly PP1. PP1 is believed to
be the primary regulator of glycogen metabolism. In skeletal
muscle, PP1 associates with a speciﬁc glycogen-binding
regulatory subunit, causing dephosphorylation (activation)
of glycogen synthase. PP1 also phosphorylates (inactivates)
glycogen phosphorylase. The precise steps that link insulin
receptor tyrosine kinase/PI3K activation to stimulation of
PP1 have yet to be deﬁned. Studies [138, 150]h a v ed e m o n -
strated convincingly that inhibitors of PI3K inhibit glycogen
synthase activity and abolish glycogen synthesis.
4.3. Insulin Receptor Signal Transduction Defects in Insulin
Resistance. Early studies have demonstrated a modest 20–
30% reduction in insulin binding to monocytes and
adipocytes from type 2 diabetic patients, but this has not
been a consistent ﬁnding [1, 151–154]. The decrease in
insulin binding is caused by a reduction in the number of
insulin receptors without change in insulin receptor aﬃnity.
Some caution, however, should be used in interpreting
these studies because muscle and liver, not adipocytes, are
the major tissues responsible for the regulation of glucose
homeostasis in vivo, and insulin binding to solubilized
receptors obtained from skeletal muscle and liver has been
shown to be normal in obese and lean diabetic individuals
[152, 153, 155]. Moreover, a decrease in insulin receptor
number cannot be demonstrated in over half of type 2
diabetic subjects, and it has been diﬃcult to demonstrate a
correlation between reduced insulin binding and the severity
ofinsulin resistance [156–158]. A variety of defectsin insulin
receptor internalization and processing have been described
in syndromes of severe insulin resistance and diabetes. The
insulin receptor gene, however, has been sequenced in a
large number of type 2 diabetic patients from diverse ethnic
populations and, with very rare exceptions, physiologically
signiﬁcant mutations in the insulin receptor gene have not
been observed [159, 160]. This excludes a structural gene
abnormality in the insulin receptor as a common cause of
insulin resistance in skeletal muscle.
4.4. Insulin Receptor Tyrosine Kinase Activity. Insulin recep-
tor tyrosine kinase activity has been examined in skeletal
muscle from normal-weight and obese diabetic subjects.
Most [1, 7, 152, 153, 156, 161]b u tn o ta l l[ 155]i n v e s t i g a t o r s
have found a reduction in tyrosine kinase activity that
cannot be explained by alterations in insulin receptor
number or insulin receptor binding aﬃnity. Restoration of
normoglycemia by weight loss, however, has been shown
to correct the defect in insulin receptor tyrosine kinase
activity [162], suggesting that the defect in tyrosine kinase
activity, at least in part, is acquired secondary to some com-
bination of hyperglycemia, distributed intracellular glucose
metabolism, hyperinsulinemia, and insulin resistance, all
of which improved after weight loss. Exposure of cultured
ﬁbroblasts to high glucose concentration also has been
shown to inhibit insulin receptor tyrosine kinase activity
[163]. Because insulin receptor tyrosine kinase activity
assays are performed in vitro, the results of these assays
could provide misleading information with regard to insulin
receptor function in vivo. To circumvent this problem, inves-
tigators have used the euglycemic hyperinsulinemic clamp
with muscle biopsies and antiphosphotyrosine immunoblot
analysis to provide a “snap shot” of the insulin-stimulated
tyrosine phosphorylation state of the receptor in vivo
[7]. In insulin-resistant obese nondiabetic subjects, in the
NGT insulin resistant oﬀspring of two diabetic parents,
and in type 2 diabetic subjects, a substantial decrease
in insulin receptor tyrosine phosphorylation has been
demonstrated. However, when insulin-stimulated insulin
receptor tyrosine phosphorylation was examined in normal-
glucose-tolerant insulin-resistant individuals (oﬀspring of
two diabetic parents) at high risk for developing type 2
diabetes, a normal increase in tyrosine phosphorylation of
the insulin receptor was observed [164]. These ﬁndings are
consistent with the concept that impaired insulin receptor
tyrosine kinase activity in type 2 diabetic patients is acquired
secondary to hyperglycemia or some other metabolic
disturbance.
4.5. Insulin-Signaling (IRS-1 and PI3K) Defects (Figure 5).
The ability of insulin to activate insulin receptor and IRS-
1 tyrosine phosphorylation in muscle in obese nondiabetic
subjects is modestly reduced; whereas in type 2 diabetics
insulin-stimulated insulin receptor and IRS-1 tyrosine phos-
phorylation are severely impaired [7]. Association of the
p85 subunit of PI3K with IRS-1 and activation of PI3K
also are greatly attenuated in obese nondiabetic and type
2 diabetic subjects compared with lean healthy controls
[7, 165, 166]. The decrease in insulin-stimulated association
of the p85 regulatory subunit of PI3K with IRS-1 is closely
correlated with the reduction in insulin-stimulated muscle
glycogen synthase activity and in vivo insulin-stimulated
glucose disposal [7]. Impaired regulation of PI3K gene
expression by insulin also is impaired in skeletal muscle,
and similar impairment has been demonstrated in adipose
tissue of type 2 diabetic subjects [167]. In animal models
of diabetes, an 80%–90% decrease in insulin-stimulated
IRS-1 phosphorylation and PI3K activity has been reported
[168, 169].Journal of Biomedicine and Biotechnology 9
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Figure 5: In insulin resistant individuals insulin signaling is
impaired at the level of IRS-1 leading to decreased glucose
transport/phosphorylation/metabolism and impaired nitric oxide
synthase activation/endothelial function. Increased intramycellar
fat and fatty acid meyabolite content and mitochondrial dysfunc-
tion also exist in skeletal muscle in insulin resistant individuals (see
text for a detailed discussion).
Intheinsulin-resistant,normalglucosetolerantoﬀspring
of two type 2 diabetic parents, IRS-1 tyrosine phospho-
rylation and the association of p85 protein/PI3K activity
with IRS-1 are markedly decreased despite normal tyro-
sine phosphorylation of the insulin receptor; these insulin
signaling defects are correlated closely with the severity
of insulin resistance measured with the euglycemic insulin
clamp technique [164]. In summary, impaired association
of PI3K with IRS-1 and its subsequent activation are
characteristic abnormalities in type 2 diabetics, and these
defects are correlated closely with in vivo muscle insulin
resistance.
The nature of the defect in IRS-1 that impairs its ability
to activate PI3-Kinase does not seem to include a structural
defect in IRS-1. A common mutation in the IRS-1 gene (Gly-
972-Arg) has been associated with type 2 diabetes, insulin
resistance, and obesity, but the physiologic signiﬁcance of
this mutation remains to be established [170]. Rodent and
human studies have suggested increased serine phosphory-
lation of IRS-1 in insulin resistant states [111, 171–173]. In
general, serine phosphorylation of IRS-1 negates its ability
to undergo tyrosine phosphorylation. Thus, conditions that
increase serine phosphorylation of IRS-1 impair tyrosine
phosphorylation by the insulin receptor and its activation,
thus, leading to an impartment in the insulin signaling
cascade. An important, yet an answered, question is the
identity of the factor(s) responsible for the activation of
serine kinases that phosphorylate IRS-1. Increased activity
of protein kinase C (PKC-β and δ has been reported in
insulin resistant states and can be induced during lipid
infusion [174, 175]. Furthermore, increased intramyocellar
levels of fat metabolites, for example, FACoA and DAG,
which are strong activators of protein kinase C, have been
demonstrated following lipid infusion [176]. Moreover,
prevention of the IRS-1 serine phosphorylation by mutating
key serine residues in the IRS-1 prevents the development
of insulin resistance in skeletal muscle caused by high-fat
feeding [169]. Increased stress kinase activity also has been
implicated in contribute to the serine phosphorylation of
IRS-1 and subsequent impairment tyrosine phosphorylation
[177, 178]. In summary, increased serine phosphorylation
of IRS-1 is believed to impair its tyrosine phosphorylation
by the insulin receptor and interrupt the insulin signalin
cascade, leading to the development of insulin resistance in
skeletal muscle.
Because nitric oxide synthase also is activated by the
IRS-1/PIS-K pathway, impaired insulin signaling leads to
reduced nitric oxide generation and endothelial dysfunction,
which have implicated in the development of accelerated
atherosclerosis in T2DM individuals.
Insulin resistance in the PI3K signaling pathway con-
trasts with an intact stimulation of the MAPK pathway
by insulin in insulin-resistant type 2 diabetic and obese
nondiabeticsindividuals[7,165].Physiologichyperinsuline-
mia increases mitogen-activated protein kinase/extracellular
signal-regulated kinase 1 activity (MEK-1) and extracellular
signal-regulated kinase1/2 phosphorylation activity (ERK)
similarly in lean healthy subjects, insulin-resistant obese
nondiabetic, and type 2 diabetic patients. Intact stimu-
lation of the MAPK pathway by insulin in the presence
of insulin resistance in the PI3K pathway may play an
important role in the development of atherosclerosis [7].
If the metabolic (PI3K) pathway is impaired, plasma glu-
cose levels rise, resulting in increased insulin secretion
and hyperinsulinemia. Because insulin receptor function is
normal or only modestly impaired, especially early in the
natural history of type 2 diabetes, this leads to excessive
stimulation of the MAPK (mitogenic) pathway in vascular
tissues, with resultant proliferation of vascular smooth
muscle cells, increased collagen formation, and increased
production of growth factors and inﬂammatory cytokines
[179, 180].
4.6. Glucose Transport. Activation of the insulin signal
transduction system in skeletal muscle stimulates glucose
transport through a mechanism that involves transloca-
tion of a large intracellular pool of glucose transporters
(associated with low-density microsomes) to the plasma
membrane and their subsequent activation after insertion
into the cell membrane [181, 182] .T h e r ea r eﬁ v em a j o r ,
diﬀerent facilitative glucose transporters (GLUTs) with dis-
tinctive tissue distributions [183, 184]. GLUT4, the insulin
regulatable transporter, is found in skeletal muscle, has a
Km of approximately 5mmol/L, which is close to that of
the plasma glucose concentration, and is associated with
HK-II [173, 174]. GLUT4 concentration in the plasma
membrane increases markedly after exposure to insulin, and
this increase is associated with a reciprocal decline in the
intracellular GLUT4 pool. A recent study has reported a
parallel translocation of GLUT12 from the cytosol to the
plasma membrane following insulin stimulation in human
skeletal muscle [185].
GLUT1 is the predominant glucose transporter in the
insulin-independent tissues (brain and erythrocytes) but
also is found in muscle and probably contributes to muscle
glucose uptake during the basal state. GLUT1 is located
primarilyintheplasmamembranewhereitsconcentrationis10 Journal of Biomedicine and Biotechnology
unchanged following exposure to insulin. Thus, it is likely to
contribute to muscle glucose uptake during the basal state. It
has a low Km (∼1mmol/L) and is well suited for its function,
which is to mediate basal glucose uptake. It is found in
association with HK-I [186].
In insulin resistant individuals with T2DM, glucose
transport activity is severely impaired [156, 181, 182, 187–
189]. Muscle tissue from lean and obese type 2 diabetic
subjects exhibits normal or increased levels of GLUT4
mRNA expression and normal levels of GLUT4 protein,
thus demonstrating that transcriptional and translational
regulation of GLUT4 is not impaired [190, 191]. Using a
noveltriple-tracertechnique,theinvivodose-responsecurve
for the action of insulin on glucose transport in forearm
skeletalmusclehasbeenexaminedintype2diabeticsubjects,
and insulin-stimulated inward muscle glucose transport has
been shown to be severely impaired [192, 193]. Impaired
in vivo muscle glucose transport in type 2 diabetics also
has been demonstrated using magnetic resonance imaging
[194] and positron emission tomography [195]. Because the
number of GLUT4 transporters in the muscle of diabetic
subjects is normal, impaired GLUT4 translocation and
decreased intrinsic activity of the glucose transporter must
be responsible for the defect in muscle glucose transport.
Large populations of type 2 diabetics have been screened for
mutationsintheGLUT4gene[196].Suchmutationsarevery
uncommon and, when detected, have been of questionable
physiologic signiﬁcance.
4.7. Glucose Phosphorylation. Glucose phosphorylation and
glucose transport are tightly coupled processes [197]. Hex-
okinase isoenzymes (HK-I–IV) catalyze the ﬁrst committed
step of glucose metabolism, the intracellular conversion
of free glucose to glucose-6-phosphate (Glu-6-P) [183,
184, 186, 198]. HK-I, HK-II, and HK-III are single-chain
peptides that have a very high aﬃnity for glucose and
demonstrate product inhibition by Glu-6-P. HK-IV, also
called glucokinase, has a lower aﬃnity for glucose and is not
inhibited by Glu-6-P.
In human skeletal muscle, HK-II transcription is reg-
ulated by insulin, whereas HK-I mRNA and protein levels
are not aﬀected by insulin [199, 200]. In response to
physiologic euglycemic hyperinsulinemia of 2 to 4 hours’
duration, HK-II cytosolic activity, protein content, and
mRNA levels increase by 50% to 200% in healthy nondia-
betic subjects, and this is associated with the translocation
of hexokinase II from the cytosol to the mitochondria.
In forearm muscle, insulin-stimulated glucose transport
(measured with the triple-tracer technique) is markedly
impaired in lean type 2 diabetics [192, 193], but the rate
of intracellular glucose phosphorylation is impaired to an
even greater extent, resulting in an increase in the free
glucose concentration within the intracellular space that is
accessible to glucose. These observations indicate that in
type 2 diabetic individuals, although both glucose transport
and glucose phosphorylation are severely resistant to the
action of insulin, impaired glucose phosphorylation (HK-II)
appearstobetherate-limitingstepforinsulinaction.Studies
using 31P nuclear magnetic resonance in combination with
[1-14C] glucose also have demonstrated that both insulin-
stimulated muscle glucose transport and glucose phospho-
rylation are impaired in type 2 diabetic subjects, but the
defect in transport exceeds the defect in phosphorylation
[194]. Because of methodologic diﬀerences, the results of the
triple-tracer technique [192, 193] and magnetic resonance
imaging [194] studies cannot be reconciled at present.
Nonetheless, these studies are consistent in demonstrating
that abnormalities in both muscle glucose phosphorylation
andglucosetransportarewellestablishedearlyinthenatural
history of type 2 diabetes and cannot be explained by glucose
toxicity.
In healthy nondiabetic subjects, a physiologic increase
in the plasma insulin concentration for as little as 2 to 4
hours increases muscle HK-II activity, gene transcription,
and translation [201]. In lean type 2 diabetics, the ability
of insulin to augment HK-II activity and mRNA levels are
markedly reduced compared with controls [199]. Decreased
basal muscle HK-II activity and mRNA levels and impaired
insulin-stimulated HK-II activity in type 2 diabetic subjects
have been reported by other investigators [200, 202]. A
decrease in insulin-stimulated muscle HK-II activity also
has been described in subjects with IGT [203]. Several
groups have looked for point mutations in the HK-II
gene in individuals with type 2 diabetes, and, although
several nucleotide substitutions have been found, none are
close to the glucose and ATP binding sites and none have
been associated with insulin resistance [203–205]. Thus,
an abnormality in the HK-II gene is unlikely to explain
the inherited insulin resistance in common variety type 2
diabetes mellitus.
4.8. Glycogen Synthesis. Impaired insulin-stimulated glyco-
gen synthesis is a characteristic ﬁnding in all insulin-
resistant states. Obese, IGT, and diabetic subjects have
severe impairment in insulin-stimulated glycogen synthase
that accounts for the majority of the defect in insulin-
mediated whole-body glucose disposal [1, 2, 21, 195, 206–
218]. Impaired glycogen synthesis also has been documented
in the normal-glucose tolerant oﬀspring of two diabetic
parents, in the ﬁrst-degree relatives of type 2 diabetic indi-
viduals, and in the normoglycemic twin of a monozygotic
twin pair in which the other twin has type 2 diabetes
[206, 210, 211].
Glycogen synthase is the key insulin-regulated enzyme
that controls the rate of muscle glycogen synthesis [148, 150,
200, 212–214]. Insulin activates glycogen synthase by stim-
ulating a cascade of phosphorylation-dephosphorylation
reactions which ultimately lead to the inhibition of glycogen
synthase kinase and activation of PP1 (also called glycogen
synthase phosphatase). The regulatory subunit of PP1 has
two serine phosphorylation sites, called site 1 and site
2. Phosphorylation of site 2 by cAMP-dependent protein
kinase inactivates PP1; whereas phosphorylation of site 1 by
insulin activates PP1, leading to the stimulation of glycogen
synthase. Phosphorylation of site 1 of PP1 by insulin in
muscle is catalyzed by insulin-stimulated protein kinase
(ISPK)-1. Because of their central role in muscle glycogen
formation, the three enzymes, glycogen synthase, PP1, andJournal of Biomedicine and Biotechnology 11
ISPK-1, have been extensively studied in individuals with
type 2 diabetes.
Glycogen synthase exists in an active (dephosphorylated)
and an inactive (phosphorylated) form [148–150]. Under
basal conditions, total glycogen synthase activity in type 2
diabetic subjects is reduced, and the ability of insulin to
activate glycogen synthase is severely impaired [7, 215–217].
The ability of insulin to stimulate glycogen synthase also is
diminished in the normal glucose-tolerant, insulin-resistant
relatives of type 2 diabetic individuals [218]. In insulin-
resistant nondiabetic and diabetic Pima Indians, activation
of muscle PP1 (glycogen synthase phosphatase) by insulin
is severely reduced [219]. Because PP1 dephosphorylates
glycogen synthase, leading to its activation, a defect in PP1
appears to play an important role in the muscle insulin
resistance of type 2 diabetes mellitus.
Theeﬀectofinsulinonglycogensynthasegenetranscrip-
tion and translation in vivo has been studied extensively.
Most studies have demonstrated that insulin does not
increase glycogen synthase mRNA or protein expression in
human muscle [201, 220, 221]. Glycogen synthase mRNA
and protein levels, however, are decreased in muscle of
type 2 diabetic patients, partly explaining the decreased
glycogensynthaseactivity[221,222].Themajorabnormality
in glycogen synthase regulation in type 2 diabetes is its lack
of dephosphorylation and activation by insulin, as a result of
insulin receptor signaling abnormalities.
The glycogen synthase gene has been the subject of
intensive investigation, and DNA sequencing has revealed
either no mutations or rare nucleotide substitutions that
cannot explain the defect in insulin-stimulated glycogen
synthaseactivity [223–225]. The genes encoding the catalytic
subunits of PP1 and ISPK-1 have been examined in Pima
Indians and Danes with type 2 diabetes [226, 227]. Several
silent nucleotide substitutions were found in the PP1 and
ISPK-1 genes in the Danish population, but the mRNA
levels of both genes were normal in skeletal muscle. No
structural gene abnormalities in the catalytic subunit of PP1
were detected in Pima Indians. Thus, neither mutations
in the PP1 and ISPK-1 genes nor abnormalities in their
translation can explain the impaired enzymatic activities of
glycogen synthase and PP1 that have been observed in vivo.
Similarly, there is no evidence that an alteration in glycogen
phosphorylase plays any role in the abnormality in glycogen
formation in type 2 diabetes [228].
In summary, glycogen synthase activity is severely
impaired in type 2 diabetic individuals, and the molecular
cause of the defect most likely is related to impaired insulin
signal transduction.
4.9. Glycolysis. Glucose oxidation accounts for approxi-
mately 90% of total glycolytic ﬂux; whereas anaerobic glycol-
ysis accounts for the other 10%. Phosphofructokinase and
pyruvate dehydrogenase play pivotal roles in the regulation
of glycolysis and glucose oxidation, respectively. In type 2
diabetic individuals, the glycolytic/glucoseoxidative pathway
has been shown to be impaired [229]. Although one study
[230] has suggested that PFK activity is modestly reduced in
muscle biopsies from type 2 diabetic subjects, most evidence
indicates that the activity of PFK is normal [216, 221].
Insulinhasnoeﬀecto nm usc lePFKacti vity ,mRN Alev els,o r
protein content in either nondiabetic or diabetic individuals
[221]. PDH is a key insulin-regulated enzyme with activity
in muscle that is acutely stimulated by insulin [231]. In type
2 diabetic patients, insulin-stimulated PDH activity has been
shown to be decreased in human skeletal muscle [231, 232].
Obesity and type 2 diabetes mellitus are associated with
accelerated FFA turnover and oxidation [1, 2, 21, 233],
which would be expected, according to the Randle cycle
[234], to inhibit PDH activity and consequently glucose
oxidation. Therefore, it is likely that the observed defects in
glucose oxidation and PDH activity are acquired secondary
to increased FFA oxidation and feedback inhibition of PDH
by elevated intracellular levels of acetyl-CoA and reduced
availability of NAD. Consistent with this scenario, the rates
of basal and insulin-stimulated glucose oxidation are not
reduced in the normal glucose-tolerant oﬀspring of two
diabetic parents and in the ﬁrst-degree relatives of type
2 diabetic subjects; whereas they are decreased in overtly
diabetic subjects.
5. Summary
In summary, a defect in the insulin signaling cascade at the
level of IRS-1 is likely the primady defect that leads to insulin
resistance in skeletal muscle. Other defects in the insulin
signaling pathway, for example, diminished insulin binding,
when present, are modest and secondary to downregulation
of the insulin receptor by chronic hyperinsulinemia. In
insulin resistant individuals with overt hyperglycemia, for
example, T2DM, a number of postbinding defects have been
demonstrated, including reduced insulin receptor tyrosine
kinase activity and altered insulin signal transduction,
decreased glucose transport, diminished glucose phospho-
rylation, and impaired glycogen synthase activity. From
the quantitative standpoint, impaired glycogen synthesis
represents the major pathway responsible for the insulin
resistance and this defect is present long before the onset of
overt diabetes, that is, in normal glucose-tolerant, insulin-
resistant prediabetic subjects, and in individuals with IGT.
The impairment in glycogen synthase activation is likely due
to a defect in the ability of insulin to phosphorylate IRS-1,
causing a reduced association of the p85 subunit of PI 3-
kinase with IRS-1 and decreased activation of the enzyme
PI3K.
Increased intramyocellar fat content and fatty acid
metabolites, for example, FACoA and DAG, are likely to
play a pivotal role in the development of insulin resistance
in skeletal muscle. Through activation of serine/threonine
kinases and serine phosphorylate the IRS-1, fatty acid
metabolites impair IRS-1 phosphorylation by the insulin
receptor and lead to the defect in insulin signaling in
insulin resistant individuals. The cause for the intramycellar
accumulation of fat and fat metabolites has yet to be deﬁned.
A mitochondrial defect in oxidative phosphorylation has
been reported in insulin resistant individuals. However, the
contriution of this mitochondrial defect to the intamyocellar
fat accumulation is not yet clear.12 Journal of Biomedicine and Biotechnology
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